1,25-dihydroxyvitamin D deficiency is independently associated with cardiac valve calcification in patients with chronic kidney disease

Il Young Kim1,2, Byung Min Ye1,2, Min Jeong Kim1,2, Seo Rin Kim1,2, Dong Won Lee1,2, Hyo Jin Kim1,3, Harin Rhee1,3, Sang Heon Song1,3, Eun Young Seong1,3 & Soo Bong Lee1,2

Cardiac valve calcification is highly prevalent in patients with chronic kidney disease (CKD). Low vitamin D levels are associated with vascular calcification in CKD. However, the association between vitamin D levels and cardiac valve calcification is unknown. A total of 513 patients with pre-dialysis CKD were included in this cross-sectional study. Aortic valve calcification (AVC) and mitral valve calcification (MVC) were assessed using two-dimensional echocardiography. The associations between AVC and MVC and baseline variables were investigated using logistic regression analyses. In multivariable analysis, serum 1,25(OH)2D level was independently associated with AVC (odds ratio [OR], 0.87; P < 0.001) and MVC (OR, 0.92; P < 0.001). Additionally, age, diabetes, coronary heart disease, calcium × phosphate product, and intact parathyroid hormone levels were independently associated with AVC and MVC. Systolic blood pressure was independently associated with AVC. A receiver-operating characteristic (ROC) curve analysis showed that the best cutoff values of serum 1,25(OH)2D levels for predicting AVC and MVC were ≤ 12.5 and ≤ 11.9 pg/dl, respectively. Serum 1,25(OH)2D deficiency is independently associated with AVC and MVC in patients with CKD, suggesting that serum 1,25(OH)2D level may be a potential biomarker of AVC and MVC in these patients.

Cardiovascular disease (CVD) is highly prevalent and the most common cause of death in patients with chronic kidney disease (CKD)1. Cardiac valve calcification is a common complication of CVD and is associated with an increased risk of CVD and all-cause mortality in patients with CKD2–5. The Kidney Disease: Improving Global Outcome (KDIGO) addressed the clinical relevance of cardiac valve calcification in CKD and suggested that cardiac valve calcification should be included in the risk stratification of CVD in patients with CKD6.

Multiple contributors, including traditional factors (age, hypertension, diabetes, and dyslipidemia) as well as non-traditional factors (hyperphosphatemia, calcium phosphate product, and parathyroid function), have been suggested to be involved in cardiac valve calcification in patients with CKD6. Vitamin D plays a central role not only in bone metabolism but also in the vasculature and may be involved in the process of vascular calcification7. Indeed, low levels of 25-hydroxyvitamin D [25(OH)D] or 1,25-dihydroxyvitamin D [1,25(OH)2D] have been reported to be associated with coronary artery and cardiac valve calcification in patients with risk factors for CVD and in the general population8–10. Vitamin D metabolism is ubiquitously altered in patients with CKD, and both 1,25(OH)2D and 25(OH)D levels are insufficient in the majority of patients with CKD11. Although an independent association between low levels of 25(OH)D and coronary artery calcification has been previously reported in patients with CKD12,13, whether vitamin D deficiency is associated with cardiac valve calcification in patients with CKD is still unknown.

In this study, we hypothesized that vitamin D deficiency would be independently associated with cardiac valve calcification and investigated the association between serum 1,25(OH)2D levels and aortic valve calcification (AVC) and mitral valve calcification (MVC) in patients with CKD.

1Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea. 2Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea. 3Medical Research Institute, Pusan National University Hospital, Busan, South Korea. *email: sbleemd@pusan.ac.kr
were likely to have decreased serum levels of calcium (P < 0.001). The levels of 1,25(OH)2D were significantly 
P < 0.001), and at least one valve calcification (CKD stages 3 vs. 4 vs. 5: 12.9% vs. 32.0% vs. 55.7%, P < 0.001) than 
stages 3 vs. 4 vs. 5: 8.5% vs. 25.4% vs. 49.2%, P < 0.001), MVC (CKD stages 3 vs. 4 vs. 5: 7.7% vs. 19.9% vs. 39.3%, 
that seen in patients with lower CKD stages.

8.3 ± 3.9 pg/dl, P < 0.001). Patients with higher CKD stages were likely to have a higher prevalence of AVC (CKD 
was used to determine the best cutoff value of serum 1,25(OH)2D levels for predicting the presence of AVC, 
characteristic (ROC) curve analysis was performed to assess the area under the curve (AUC) and Youden index 
and multivariable logistic regression analyses were used to determine the factors for predicting the presence of 
Comparisons between the three CKD stage groups or three 1,25(OH)2D tertile groups were performed with a 
one-way analysis of variance for continuous variables and the chi-square test for categorical variables. Univariate 
ables are expressed as means ± standard deviations, while categorical variables are presented as percentages. 
Continuous variables are expressed as means ± standard deviations, while categorical variables are presented as percentages. Comparisons between the three CKD stage groups or three 1,25(OH)2D tertile groups were performed with a 
one-way analysis of variance for continuous variables and the chi-square test for categorical variables. Univariate 
and multivariable logistic regression analyses were used to determine the factors for predicting the presence of 
AUC and MVC. Significant variables were identified by univariate analysis, and the clinically important variables were selected for multivariable analysis. A receiver-operating characteristic (ROC) curve analysis was performed to assess the area under the curve (AUC) and Youden index 
was used to determine the best cutoff value of serum 1,25(OH)2D levels for predicting the presence of AVC, 
MVC, or at least one valve calcification. Statistical significance was set at P < 0.05. All analyses were performed using the SPSS version 26.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc Statistical Software version 19.4.1 (MedCalc Software, Ostend, Belgium).

Results
Study population. Baseline characteristics of the study population according to CKD stage were summarized in Supplementary Table S1. Of the 513 patients included in the study, 271 had CKD stage 3; 181, CKD stage 4; and 61, CKD stage 5. The mean eGFRs were 42.2 ± 8.2, 22.1 ± 4.6, and 10.2 ± 4.5 ml/min/1.73 m2 in the CKD stages 3, 4, and 5 groups, respectively (P < 0.001). Regarding the biochemical parameters of CKD-mineral and bone disorder (MBD), patients with higher CKD stages were likely to have elevated serum levels of phosphate (P < 0.001), calcium × phosphate (Ca × P) product (P < 0.001), and intact PTH (P < 0.001), whereas they were likely to have decreased serum levels of calcium (P < 0.001). The levels of 1,25(OH)2D were significantly different between the three CKD stage groups (CKD stages 3 vs. 4 vs. 5: 22.0 ± 10.7 pg/dl vs. 15.1 ± 9.1 pg/dl vs. 8.3 ± 3.9 pg/dl, P < 0.001). Patients with higher CKD stages were likely to have a higher prevalence of AVC (CKD stages 3 vs. 4 vs. 5: 8.5% vs. 25.4% vs. 49.2%, P < 0.001), MVC (CKD stages 3 vs. 4 vs. 5: 7.7% vs. 19.9% vs. 39.3%, P < 0.001), and at least one valve calcification (CKD stages 3 vs. 4 vs. 5: 12.9% vs. 32.0% vs. 55.7%, P < 0.001) than that seen in patients with lower CKD stages.

Table 1 shows the baseline characteristics of three 1,25(OH)2D tertile groups. There were significant differences between the three groups in age (P = 0.001); prevalence of diabetes (P = 0.007) and coronary heart disease (P = 0.014); systolic (P < 0.001) and diastolic (P = 0.006) blood pressure; levels of urinary albumin (P = 0.001) and serum phosphate (P < 0.001), Ca × P product (P < 0.001), homoglobin (P < 0.001), CRP (P < 0.001), intact PTH
There were also significant differences between the three groups in prevalence of AVC (P < 0.001), MVC (P < 0.001), and at least one valve calcification (P < 0.001).

### Association between serum 1,25(OH)2D levels and cardiac valve calcification.

The association between the presence of AVC and baseline variables are shown in Table 2. A univariate logistic regression analysis revealed that age, diabetes, coronary heart disease, cerebrovascular disease, systolic and diastolic blood pressure, eGFR, and the levels of urinary albumin and serum albumin, Ca × P product, hemoglobin, CRP, intact PTH, and 1,25(OH)2D were significantly associated with AVC. In a multivariable logistic regression analysis, serum 1,25(OH)2D level (odds ratio [OR]: 0.87, 95% confidence interval [CI]: 0.82–0.91, P < 0.001) was independently associated with AVC. In addition, age (OR: 0.016, 95% CI 1.00–1.08, P = 0.016), diabetes (OR: 2.07, 95% CI 1.06–4.03, P = 0.033), coronary heart disease (OR: 2.71, 95% CI 1.18–6.24, P = 0.019), systolic blood pressure (OR: 1.29, 95% CI 1.03–1.62, P = 0.030), and serum Ca × P product (OR: 1.05, 95% CI 1.01–1.10, P = 0.001) and intact PTH levels (OR: 1.14, 95% CI 1.04–1.24, P < 0.001) were independently associated with AVC.

Table 3 shows the baseline variables associated with the presence of MVC. A univariate logistic regression analysis revealed that age, diabetes, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressure, eGFR, and the levels of urinary albumin and serum albumin, Ca × P product, hemoglobin, CRP, intact PTH, and 1,25(OH)2D were significantly associated with MVC. A multivariable logistic regression

---

**Table 1.** Baseline characteristics of the study population according to tertiles of serum 1,25(OH)2D levels (n = 513). Data are presented as mean ± standard deviation or (n, %). aCoronary heart disease is defined as a history of coronary artery bypass surgery or percutaneous transluminal coronary angioplasty. bCerebrovascular disease is defined as a history of stroke or transient ischemic attack. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blockers, Ca × P product, calcium × phosphorus product, CKD chronic kidney disease, CRP C-reactive protein, eGFR estimated glomerular filtration rate, PTH parathyroid hormone, 1,25(OH)2D 1,25-dihydroxyvitamin D.

| Tertile 1 (< 11.5 pg/dl) | Tertile 2 (11.5–21.4 pg/dl) | Tertile 3 (> 21.4 pg/dl) | P     |
|-------------------------|-----------------------------|-------------------------|-------|
| Age (years)             | 61.9 ± 10.5                 | 61.2 ± 9.7              | 58.1 ± 10.0 | 0.001 |
| Sex, male [n (%)]       | 86 (51.5%)                  | 88 (50.6%)              | 89 (51.7%) | 0.974 |
| Current smoking [n (%)] | 25 (15.0%)                  | 25 (14.4%)              | 35 (20.3%) | 0.260 |
| Diabetes [n (%)]        | 88 (52.7%)                  | 103 (59.2%)             | 73 (42.4%) | 0.007 |

**Cardiovascular disease [n (%)]**

| Coronary heart diseasea | 47 (28.1%)                  | 38 (21.8%)              | 26 (15.1%) | 0.014 |
| Cerebrovascular diseasb | 17 (10.2%)                  | 12 (6.9%)               | 25 (14.5%) | 0.068 |
| Peripheral vascular disease | 15 (9.0%)                   | 16 (9.2%)               | 7 (4.1%)   | 0.122 |

**Medication [n (%)]**

| ACEI or ARB | 129 (77.2%)                  | 133 (76.4%)              | 129 (78.0%) | 0.886 |
| Calcium channel blockers | 111 (66.5%)                  | 103 (59.2%)              | 98 (57.0%)  | 0.174 |
| Beta-blockers | 68 (40.7%)                   | 67 (38.5%)               | 60 (34.9%)  | 0.535 |
| Diuretics (thiazide) | 41 (24.6%)                   | 53 (30.5%)               | 59 (34.3%)  | 0.142 |
| Diuretics (loop) | 81 (48.5%)                   | 73 (42.0%)               | 66 (38.4%)  | 0.162 |
| Anti-platelet agents | 57 (34.1%)                   | 61 (35.1%)               | 40 (23.3%)  | 0.031 |
| Statins | 66 (39.5%)                   | 60 (34.5%)               | 54 (31.4%)  | 0.587 |
| Body mass index (kg/m²) | 23.8 ± 2.3                   | 23.5 ± 2.5               | 23.7 ± 2.4  | 0.003 |
| Systolic blood pressure (mmHg) | 140.7 ± 19.3             | 134.2 ± 17.9             | 128.6 ± 19.8 | < 0.001 |
| Diastolic blood pressure (mmHg) | 81.8 ± 15.1                | 78.8 ± 12.7              | 77.0 ± 13.5 | 0.006 |
| eGFR (ml/min/1.73 m²) | 23.1 ± 12.2                 | 33.8 ± 13.8              | 36.7 ± 11.5 | < 0.001 |
| Urinary albumin (mg/g Cr) | 1473.5 ± 1322.6             | 1230.7 ± 1113.0          | 1010.4 ± 975.4 | 0.001 |
| Albumin (g/dl) | 4.0 ± 0.4                    | 4.1 ± 0.4                | 4.2 ± 0.3   | < 0.001 |
| Uric acid (mg/dl) | 7.7 ± 2.7                    | 7.1 ± 2.9                | 7.4 ± 2.7   | 0.216 |
| Calcium (mg/dl) | 9.2 ± 0.6                    | 9.2 ± 0.7                | 9.3 ± 0.4   | 0.820 |
| Phosphate (mg/dl) | 4.6 ± 1.0                    | 4.1 ± 0.9                | 3.6 ± 0.7   | < 0.001 |
| Ca × P product (mg²/dl²) | 42.6 ± 10.0                  | 37.5 ± 8.5               | 33.7 ± 6.5  | < 0.001 |
| Total cholesterol (mg/dl) | 215.1 ± 42.4                | 212.8 ± 44.3             | 205.7 ± 37.4 | 0.094 |
| Hemoglobin (g/dl) | 11.0 ± 1.8                   | 11.9 ± 1.8               | 12.2 ± 1.8  | < 0.001 |
| CRP (mg/dl) | 1.0 ± 1.1                    | 0.7 ± 0.6                | 0.8 ± 0.8   | < 0.001 |
| Intact PTH (pg/ml) | 124.1 ± 67.0                 | 81.4 ± 56.6              | 66.3 ± 45.1 | < 0.001 |
| Aortic valve calcification [n (%)] | 71 (42.5%)                 | 23 (13.2%)               | 5 (2.9%)   | < 0.001 |
| Mitral valve calcification [n (%)] | 54 (32.3%)                | 20 (11.5%)               | 7 (4.1%)   | < 0.001 |
| At least one valve calcification [n (%)] | 86 (51.5%)               | 32 (18.4%)               | 9 (5.2%)  | < 0.001 |

(P < 0.001), eGFR (P = 0.001), and serum albumin level (P < 0.001). There were also significant differences between the three groups in prevalence of AVC (P < 0.001), MVC (P < 0.001), and at least one valve calcification (P < 0.001).
analysis revealed that 1,25(OH)\(_2\)D level (OR, 0.92; 95% CI 0.88–0.97, \(P = 0.001\)) was independently associated with MVC. Furthermore, age (OR: 1.04, 95% CI 1.00–1.07, \(P = 0.030\)), diabetes (OR: 2.28, 95% CI 1.19–4.36, \(P = 0.013\)), coronary heart disease (OR: 2.77, 95% CI 1.27–6.05, \(P = 0.011\)), and serum Ca × P product (OR: 1.04, 95% CI 1.01–1.08, \(P = 0.025\)) and intact PTH levels (OR: 1.09, 95% CI 1.01–1.18, \(P = 0.024\)) were independently associated with MVC.

Table 4 shows the baseline variables associated with the presence of at least one valve calcification (AVC or MVC). A univariate logistic regression analysis showed that age, diabetes, coronary heart disease, cerebrovascular disease, systolic and diastolic blood pressure, eGFR, and the levels of urinary albumin and serum albumin, Ca × P product, hemoglobin, CRP, intact PTH, and 1,25(OH)\(_2\)D were associated with at least one valve calcification. Multivariable logistic regression analysis showed that serum 1,25(OH)\(_2\)D level (OR: 0.88, 95% CI 0.84–0.92, \(P < 0.001\)) was an independent predictor of at least one valve calcification. Age (OR: 1.05, 95% CI 1.01–1.09, \(P = 0.002\)), diabetes (OR: 2.25, 95% CI 1.21–4.20, \(P = 0.011\)), coronary heart disease (OR: 2.91, 95% CI 1.29–6.54, \(P = 0.010\)), peripheral vascular disease (OR: 2.86, 95% CI 1.02–7.99, \(P = 0.045\)), and the serum levels of Ca × P product (OR: 1.09, 95% CI 1.05–1.13, \(P < 0.001\)) and intact PTH (OR: 1.18, 95% CI 1.08–1.28, \(P < 0.001\)) were also independently associated with at least one valve calcification.

Performance of serum 1,25(OH)\(_2\)D level for predicting the presence of cardiac valve calcification. ROC analysis was performed to investigate the diagnostic power of serum 1,25(OH)\(_2\)D levels in predicting the presence of AVC, MVC, and at least one valve calcification (Fig. 1). The AUCs for serum 1,25(OH)\(_2\)D levels were 0.819 (95% CI 0.783–0.852, \(P < 0.001\)) for AVC, 0.762 (95% CI 0.722–0.798, \(P < 0.001\)) for MVC, and 0.803 (95% CI 0.766–0.837, \(P < 0.001\)) for at least one valve calcification. The best cutoff value of
serum 1,25(OH)2D level for predicting the presence of AVC was ≤ 12.5 pg/dl with an associated sensitivity of 80.8% and specificity of 70.0%. The best cutoff of serum 1,25(OH)2D level for predicting the presence of MVC was ≤ 11.9 pg/dl with an associated sensitivity of 71.6% and specificity of 70.8%. Finally, the best cutoff value of serum 1,25(OH)2D level for predicting the presence of at least one valve calcification was ≤ 12.5 pg/dl with an associated sensitivity of 76.4% and specificity of 72.3%.

**Discussion**

Vascular calcification has received growing attention in patients with CKD, as accumulating evidence suggests that vascular calcification is one of the major causes of CVD in patients with CKD18. However, research has focused on the pathophysiology and clinical impact of vascular calcification as an important part of CKD-MBD, with less attention being paid to cardiac valve calcification in patients with CKD19. However, cardiac valve calcification has been reported to be associated with an increased risk of CVD and death in patients with CKD19. Therefore, verifying the risk factors for cardiac valve calcification is clinically important for improving the prognosis of patients with CKD. In this study, we investigated the associations between various clinical variables and cardiac valve calcification and found that serum 1,25(OH)2D level is an independent risk factor for cardiac valve calcification in patients with CKD.

As the CKD stage increases, cardiac valve calcification is more frequently observed, with the prevalence of AVC increasing from 23% in CKD to 54% in hemodialysis patients, and of MVC, from 25% in CKD to 45% in hemodialysis patients6,19. Consistent with previous reports, our study found that the overall prevalence of AVC was 19.3% (8.5%, 25.4%, and 49.2% in patients with CKD stages 3, 4, and 5, respectively) and that of MVC was 15.8% (7.7%, 19.9%, and 39.3% in patients with CKD stages 3, 4, and 5, respectively) in patients with pre-dialysis

### Table 3

| Variable                        | Univariate       | Multivariable     |
|---------------------------------|------------------|------------------|
|                                | Odds ratio (95% CI) | P     | Odds ratio (95% CI) | P     |
| Age (1 year)                    | 1.09 (1.06–1.12) | <0.001 | 1.04 (1.00–1.07) | 0.030 |
| Sex, male                       | 0.91 (0.57–1.47) | 0.712 | 0.86 (0.48–1.57) | 0.632 |
| Current smoking                 | 0.97 (0.50–1.82) | 0.891 |                   |       |
| Diabetes                        | 2.58 (1.55–4.31) | <0.001 | 2.28 (1.19–4.36) | 0.013 |
| **Cardiovascular disease**      |                  |       |                   |       |
| Coronary heart disease*          | 3.34 (2.01–5.53) | <0.001 | 2.77 (1.27–6.05) | 0.011 |
| Cerebrovascular disease*         | 2.55 (1.35–4.84) | 0.004 | 2.06 (0.78–5.44) | 0.146 |
| Peripheral vascular disease      | 1.74 (0.79–3.82) | 0.170 |                   |       |
| **Medication**                  |                  |       |                   |       |
| ACEI or ARB                      | 1.11 (0.63–1.96) | 0.720 |                   |       |
| Calcium channel blockers         | 1.19 (0.72–1.94) | 0.498 |                   |       |
| Beta-blockers                    | 1.46 (0.90–2.35) | 0.123 |                   |       |
| Diuretics (thiazide)             | 0.68 (0.39–1.19) | 0.174 |                   |       |
| Diuretics (loop)                 | 1.29 (0.80–2.07) | 0.298 |                   |       |
| Anti-platelet agents             | 1.07 (0.65–1.79) | 0.783 |                   |       |
| Statins                          | 1.18 (0.72–1.92) | 0.513 |                   |       |
| Body mass index (1 kg/m²)        | 1.00 (0.91–1.10) | 0.973 |                   |       |
| Systolic blood pressure (10 mmHg)| 1.43 (1.24–1.65) | <0.001 | 1.09 (0.88–1.36) | 0.431 |
| Diastolic blood pressure (10 mmHg)| 1.32 (1.11–1.57) | 0.002 | 0.94 (0.73–1.22) | 0.651 |
| eGFR (1 ml/min/1.73 m²)          | 0.93 (0.91–0.95) | <0.001 | 1.01 (0.97–1.05) | 0.661 |
| Urinary albumin (100 mg/g Cr)    | 1.03 (1.01–1.05) | 0.001 | 0.99 (0.96–1.02) | 0.666 |
| Albumin (1 ng/dl)                | 0.45 (0.25–0.81) | 0.008 | 1.36 (0.54–3.34) | 0.510 |
| Uric acid (1 mg/dl)              | 1.06 (0.98–1.16) | 0.168 |                   |       |
| Ca × P product (1 mg/dl²)        | 1.12 (1.09–1.15) | <0.001 | 1.04 (1.01–1.08) | 0.025 |
| Total cholesterol (1 mg/dl)      | 1.00 (0.99–1.01) | 0.818 |                   |       |
| Hemoglobin (1 g/dl)              | 0.68 (0.59–0.79) | <0.001 | 0.91 (0.75–1.10) | 0.319 |
| CRP (1 mg/dl)                    | 1.46 (1.15–1.85) | 0.002 | 0.95 (0.67–1.36) | 0.790 |
| Intact PTH (10 pg/ml)            | 1.19 (1.14–1.24) | <0.001 | 1.09 (1.01–1.18) | 0.024 |
| 1,25(OH)2D (1 pg/dl)             | 0.89 (0.86–0.92) | <0.001 | 0.92 (0.88–0.97) | 0.001 |

serum 1,25(OH)2D level for predicting the presence of AVC was ≤ 12.5 pg/dl with an associated sensitivity of 80.8% and specificity of 70.0%. The best cutoff of serum 1,25(OH)2D level for predicting the presence of MVC was ≤ 11.9 pg/dl with an associated sensitivity of 71.6% and specificity of 70.8%. Finally, the best cutoff value of serum 1,25(OH)2D level for predicting the presence of at least one valve calcification was ≤ 12.5 pg/dl with an associated sensitivity of 76.4% and specificity of 72.3%.
CKD. The cardiac valve consists of valve endothelial cells and valvular interstitial cells (VICs). Cardiac valve calcification shares common pathophysiological factors with vascular calcification in patients with CKD. Endothelial dysfunction and calcification of interstitial cells of the valve leaflets are the main pathophysiological features of cardiac valve calcification. The process of cardiac valve calcification is complex, and numerous factors can contribute to its pathogenesis and progression. Advanced age, high blood pressure, genetic factors, mechanical stress, metabolic factors (dyslipidemia, diabetes, metabolic syndrome, and metabolic uremic factors), inflammation, mineral/hormone-related factors (hyperphosphatemia and Ca × P product and PTH levels), and drugs, including calcium-based phosphate binders, have been suggested as risk factors for cardiac valve calcification in patients with CKD.

Consistent with the findings of previous studies, the multivariable analyses in our study showed that age (for AVC and MVC), systolic blood pressure (for AVC), coronary heart disease (for AVC and MVC), diabetes (for AVC and MVC), and Ca × P product (for AVC and MVC) and intact PTH levels (for AVC and MVC) were independently associated with cardiac valve calcification in patients with CKD.

Previous studies have suggested the potential role of vitamin D and in various types of kidney disease. Vitamin D insufficiency is common and leads to secondary hyperparathyroidism in patients with CKD. Vitamin D compounds remain the first-line therapy for the treatment of secondary hyperparathyroidism (SHPT). Vitamin D is known to be associated with renal tubular homeostasis. The protective role of vitamin D against chronic inflammation observed in tubular injury has been demonstrated in animal and human studies. In glomerulonephritis, vitamin D preserves the structural integrity of the slit diaphragm, significantly prevents the loss of nephrin, podocin, and tight junction protein. In diabetic nephropathy, growing evidence has suggested that vitamin D might have anti-proteinuric, anti-inflammatory, and renoprotective effects. Finally, prospective randomized studies are needed to determine the role of vitamin D in those kidney diseases.

Table 4. Univariate and multivariable analyses for variables associated with at least one valve calcification in the study population (n = 513). Data are presented as odds ratio and 95% confidence interval (CI).

|                                | Univariable | Multivariable |
|--------------------------------|-------------|---------------|
|                                | Odds ratio (95% CI) | P   | Odds ratio (95% CI) | P   |
| Age (1 year)                   | 1.08 (1.06–1.11)   < 0.001 | 1.05 (1.01–1.09)   0.002 |
| Sex, male                      | 0.88 (0.59–1.31)   0.525 | 0.77 (0.42–1.39)   0.385 |
| Current smoking                | 1.07 (0.63–1.83)   0.792 |               |             |
| Diabetes                       | 2.24 (1.47–3.40)   < 0.001 | 2.25 (1.21–4.20)   0.011 |
| **Cardiovascular disease**     |             |               |               |             |
| Coronary heart disease*        | 3.12 (1.99–4.88)   < 0.001 | 2.91 (1.29–6.54)   0.010 |
| Cerebrovascular disease*       | 2.12 (1.18–3.82)   0.012 | 1.85 (0.69–4.97)   0.225 |
| Peripheral vascular disease    | 1.87 (0.94–3.73)   0.077 | 2.86 (1.02–7.99)   0.045 |
| **Medication**                 |             |               |               |             |
| ACEI or ARB                     | 1.37 (0.84–2.25)   0.212 |               |             |
| Calcium channel blockers        | 1.03 (0.69–1.56)   0.873 |               |             |
| Beta-blockers                   | 1.23 (0.82–1.85)   0.320 |               |             |
| Diuretics (thiazide)            | 0.66 (0.42–1.05)   0.079 |               |             |
| Diuretics (loop)                | 1.38 (0.92–2.06)   0.120 |               |             |
| Anti-platelet agents            | 1.21 (0.79–1.85)   0.390 |               |             |
| Statins                         | 1.34 (0.89–2.02)   0.168 |               |             |
| Body mass index (1 kg/m2)       | 1.05 (0.96–1.13)   0.288 |               |             |
| Systolic blood pressure (10 mmHg) | 1.53 (1.34–1.75)   < 0.001 | 1.12 (0.91–1.38)   0.294 |
| Diastolic blood pressure (10 mmHg) | 1.47 (1.26–1.71)   < 0.001 | 1.17 (0.90–1.54)   0.242 |
| eGFR (1 ml/min/1.73 m2)         | 0.93 (0.91–0.95)   < 0.001 | 1.02 (0.98–1.06)   0.328 |
| Urinary albumin (100 mg/g Cr)   | 1.03 (1.01–1.04)   0.002 | 0.99 (0.96–1.02)   0.495 |
| Albumin (1 mg/dl)               | 0.52 (0.31–0.87)   0.012 | 1.97 (0.72–5.39)   0.189 |
| Uric acid (1 mg/dl)             | 1.04 (0.96–1.11)   0.346 |               |             |
| Ca × P product (1 mg/dl2)       | 1.15 (1.11–1.18)   < 0.001 | 1.09 (1.05–1.13)   < 0.001 |
| Total cholesterol (1 mg/dl)     | 1.00 (1.00–1.01)   0.694 |               |             |
| Hemoglobin (1 g/dl)             | 0.72 (0.64–0.82)   < 0.001 | 1.02 (0.85–1.24)   0.814 |
| CRP (1 mg/dl)                   | 1.80 (1.42–2.28)   < 0.001 | 1.27 (0.89–1.80)   0.184 |
| Intact PTH (10 pg/ml)           | 1.22 (1.17–1.27)   < 0.001 | 1.18 (1.08–1.28)   < 0.001 |
| 1,25(OH)2D (1 pg/dl)            | 0.86 (0.84–0.89)   < 0.001 | 0.88 (0.84–0.92)   < 0.001 |

ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, Ca × P product, calcium × phosphorus product, CKD chronic kidney disease, CRP C-reactive protein, eGFR estimated glomerular filtration rate, PTH parathyroid hormone, 1,25(OH)2D 1,25-dihydroxyvitamin D.
is the first study to report an association between serum vitamin D deficiency (measured by serum 1,25(OH)2D levels) and cardiac valve calcification, which triggered the differentiation of VICs into osteoblast-like cells28. Another study by Dishmon et al. showed that low levels of serum 25(OH)D are associated with cardiac valve calcification in patients with CKD. Concerning the association between vitamin D deficiency and cardiac valve calcification, several studies have reported this association in patients with diseases other than CKD. Dishmon et al. showed that low levels of serum 25(OH)D are associated with cardiac valve calcification in patients with dilated cardiomyopathy without significant renal dysfunction25. Yusuf et al. reported that serum 25(OH)D levels correlated with the severity of valvular calcification in patients with rheumatic mitral stenosis26. Tibaukuu et al. reported a possible link between serum 25(OH)D level and the risk of incident mitral annulus calcification, but not AVC, in the general population free of preexisting clinical CVD10. To our knowledge, this is the first study to report an association between serum vitamin D deficiency (measured by serum 1,25(OH)2D levels) and cardiac valve calcification in patients with CKD.

Our study demonstrated an independent association between serum 1,25(OH)2D and cardiac valve calcification even after adjustment for several confounding factors of CKD-MBD (calcium, phosphate, Ca × P product, and intact PTH levels), suggesting a direct causal role of low serum 1,25(OH)2D levels in cardiac valve calcification in patients with CKD. However, the pathophysiological explanation for the association between serum 1,25(OH)2D levels and cardiac valve calcification in patients with CKD is still unclear. One possible mechanism is that vitamin D may be involved in the differentiation of VICs into osteoblast-like cells. VICs are a major cellular component of cardiac valve leaflets. As valvular calcification progresses, a subpopulation of VICs undergoes a phenotypic transformation into osteoblast-like cells27. Osteoblast-like cells may be involved in the development of valvular calcification as osteoblasts play a central role in bone development27. Schmidt et al. showed that a low vitamin diet accelerated valvular calcification by differentiating VICs into osteoblast-like cells in an animal model, suggesting a causal role of vitamin D deficiency in valvular calcification28. In another report by Schmidt et al., vitamin D receptor (VDR) deficiency promoted AVC in a VDR−/− mouse model via upregulation of osteoblast transcription factors, which triggered the differentiation of VICs into osteoblast-like cells28. Another potential mechanism underlying the vitamin D–cardiac valve calcification association is inflammation. It is well established that inflammation promotes valvular calcification29–31. VDR is abundantly expressed in immune cells, and vitamin D has potent anti-inflammatory properties29. While physiological levels of vitamin D are capable of inhibiting calcification by modulating inflammation, vitamin D deficiency observed in patients with CKD leads to a pro-inflammatory activity that may subsequently drive calcification29. However, the question remains whether vitamin D supplements can delay the progression of cardiac valve calcification in patients with CKD. With regard to vascular calcification, the 2017 KDIGO guidelines on CKD-MBD recommend avoiding calcitriol and vitamin D analog supplementation in patients with CKD not on dialysis because excessive vitamin D supplementation can cause hypercalcemia and hyperphosphatemia, which may promote vascular calcification31. If initiated for severe and progressive SHPT, calcitriol or vitamin D analogs should be started with low doses, and then titrated based on the PHT response. Thus, the 2017 KDIGO guidelines suggest that calcitriol and vitamin D analogs not be routinely used in patients with CKD not on dialysis31. As to cardiac valve calcification, excessive vitamin D supplementation was shown to be associated with AVC in an animal model32. Further clinical studies are needed to verify the effect of vitamin D supplementation on cardiac valve calcification in patients with CKD.

There were several limitations to the present study. First, owing to its retrospective and cross-sectional design, it was difficult to establish a temporal and causal relationship between serum 1,25(OH)2D levels and cardiac valve calcification. Second, the sample size was relatively small, which might have limited the power of the study. Third, the study was not randomized, which might have introduced bias. Despite these limitations, the study provides valuable insights into the role of vitamin D in cardiac valve calcification. Further research is needed to confirm these findings and to explore potential therapeutic strategies for preventing cardiac valve calcification.

Figure 1. Receiver-operating characteristic curves of serum 1,25(OH)2D levels for predicting the presence of AVC (a), MVC (b) or at least one valve calcification (c) in patients with pre-dialysis CKD (n = 513). The areas under the curve for serum 1,25(OH)2D levels were 0.819 [95% confidence interval (CI): 0.783–0.852, P < 0.001] for AVC, 0.762 (95% CI 0.722–0.798, P < 0.001) for MVC, and 0.803 (95% CI 0.766–0.837, P < 0.001) for at least one valve calcification. The best cutoff value of serum 1,25(OH)2D level for predicting the presence of AVC was ≤ 12.5 pg/dl with an associated sensitivity of 80.8% and specificity of 70.0%. The best cutoff of serum 1,25(OH)2D level for predicting the presence of MVC was ≤ 11.9 pg/dl with an associated sensitivity of 71.6% and specificity of 70.8%. Finally, the best cutoff value of serum 1,25(OH)2D level for predicting the presence of at least one valve calcification was ≤ 12.5 pg/dl with an associated sensitivity of 76.4% and specificity of 72.3%.
valve calcification. Further experimental and clinical studies are needed to establish the causal relationship between serum 1,25(OH)₂D levels and cardiac valve calcification in patients with CKD. Second, this study did not include fibroblast growth factor (FGF)23, which is one of the major components of CKD-MBD, in the analysis due to the retrospective design of this study. FGF23 is known to inhibit 1α-hydroxylase. Early in CKD, the decline in 1,25(OH)₂D levels is likely due to the increase in FGF23 levels rather than the loss of functional renal mass. Thus, if FGF23 levels had been included in the analysis, the association between serum 1,25(OH)₂D and cardiac valve calcification could have been addressed in greater detail.

Nevertheless, the present study had several strengths. First, serum 1,25(OH)₂D levels were measured instead of those of 25(OH)D. The levels of 1,25(OH)₂D reflect the true biological activity of vitamin D because this form binds to VDR, whereas 25(OH)D levels reflect the vitamin D stores because it is the main circulating form of vitamin D. We think that the results of this study are more physiologically relevant than those of previous studies that measured 25(OH)D levels. Second, to unveil the association between vitamin D and cardiac valve calcification more clearly, we excluded the patients who were taking vitamin D supplements, calcimimetics, and phosphate binders, which could affect endogenous vitamin D metabolism. Third, we showed not only an independent association between serum 1,25(OH)₂D levels and cardiac valve calcification but also the best cutoff values of serum 1,25(OH)₂D levels to predict the presence of cardiac valve calcification, suggesting that serum 1,25(OH)₂D levels may be a biomarker for cardiac valve calcification in patients with CKD.

In conclusion, our study demonstrates that serum 1,25(OH)₂D level is independently associated with cardiac valve calcification and may be a potential biomarker for cardiac valve calcification in patients with CKD. Future studies are needed to demonstrate the role of vitamin D in the pathogenesis of cardiac valve calcification in CKD and to determine whether vitamin D therapy can prevent the progression of cardiac valve calcification in patients with CKD.

Data availability
All data generated or analyzed during this study are included in this published article and its Supplementary Information files.

Received: 13 July 2021; Accepted: 5 January 2022
Published online: 18 January 2022

References
1. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N. Engl. J. Med.* 351(13), 1296–1305 (2004).
2. Ik, J. H. et al. Kidney function and aortic valve and mitral annular calcification in the multi-ethnic study of atherosclerosis (MESA). *Am. J. Kidney Dis.* 50(3), 412–420 (2007).
3. Raggi, P. et al. All-cause mortality in hemodialysis patients with heart valve calcification. *Clin. J. Am. Soc. Nephrol.* 6(8), 1990–1995 (2011).
4. Wang, A. Y. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. *J. Am. Soc. Nephrol.* 14(1), 159–168 (2003).
5. Sharma, R. et al. Mitral annular calcification predicts mortality and coronary artery disease in end stage renal disease. *Atherosclerosis* 191(2), 348–354 (2007).
6. Marwick, T. H. et al. Chronic kidney disease and valvular heart disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference. *Kidney Int.* 96(4), 836–849 (2019).
7. Brahmhhatt, S., Mihkhali, M., Islam, S. & Aloya, J. F. Vitamin D and abdominal aortic calcification in older African American women, the PODA clinical trial. *Nutrients* 12, 3 (2020).
8. Doherty, T. M. et al. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. *Circulation* 96(5), 1477–1481 (1997).
9. Watson, K. E. et al. Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation* 96(6), 1755–1760 (1997).
10. Tilakavu, M. et al. Relation of serum vitamin D to risk of mitral annular and aortic valve calcium (from the multi-ethnic study of atherosclerosis). *Am. J. Cardiol.* 120(3), 473–478 (2017).
11. Lim, K., Hamano, T. & Thadhani, R. Vitamin D and calcimimetics in cardiovascular disease. *Semin. Nephrol.* 38(3), 251–266 (2018).
12. de Boer, I. H. et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. *J. Am. Soc. Nephrol.* 20(8), 1805–1812 (2009).
13. Oh, K. H. et al. The KNOW–CKD study: What we have learned about chronic kidney diseases. *Kidney Res. Clin. Pract.* 39(2), 121–135 (2020).
14. Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann. Intern. Med.* 130(6), 461–470 (1999).
15. Kim, I. Y. et al. Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. *PLoS ONE* 16(5), e0251333 (2021).
16. Kim, I. Y. et al. Cardiac valve calcification is associated with presence and severity of coronary artery disease in patients with pre-dialysis chronic kidney disease. *Clin. Exp. Nephrol.* 19(6), 1090–1097 (2015).
17. Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J. Am. Soc. Echocardiogr.* 28(1), 1–39 (2015).
18. Brandenburg, V. M., Schuh, A. & Kramann, R. Valvular calcification in chronic kidney disease. *Adv. Chronic Kidney Dis.* 26(6), 464–471 (2019).
19. Urena-Torres, P. et al. Valvular heart disease and calcification in CKD: More common than appreciated. *Nephrol. Dial. Transplant.* 35(12), 2046–2053 (2020).
20. Rong, S. et al. Risk factors for heart valve calcification in chronic kidney disease. *Medicine (Baltimore)* 97(5), e9804 (2018).
21. Jean, G., Souberbielle, J. C. & Chazot, C. Vitamin D in chronic kidney disease and dialysis patients. *Nutrients* 9, 4 (2017).
22. Gembillo, G. et al. Protective role of vitamin D in renal tubulopathies. *Metabolites* 10, 3 (2020).
23. Gembillo, G., Siligato, R., Amatruda, M., Conti, G. & Santoro, D. Vitamin D and Glomerulonephritis. *Medicina (Kaunas)* 57, 2 (2021).
24. Gembillo, G. *et al.* Role of vitamin D status in diabetic patients with renal disease. *Medicina* 55, 6 (2019).
25. Dishmon, D. A. *et al.* Hypovitaminosis D and valvular calcification in patients with dilated cardiomyopathy. *Am. J. Med. Sci.* 337(5), 312–316 (2009).
26. Yusuf, J., Mukhopadhyay, S., Vignesh, V. & Tyagi, S. Evaluation of serum 25-hydroxyvitamin D levels in calcific rheumatic mitral stenosis—A cross sectional study. *Indian Heart J.* 70(2), 206–213 (2018).
27. Liu, A. C., Joag, V. R. & Gotlieb, A. I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. *Am. J. Pathol.* 171(5), 1407–1418 (2007).
28. Schmidt, N. *et al.* Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. *PLoS ONE* 7(4), e35316 (2012).
29. Sallam, T., Tintut, Y. & Demer, L. L. Regulation of calcific vascular and valvular disease by nuclear receptors. *Curr. Opin. Lipidol.* 30(5), 357–363 (2019).
30. Wang, J., Zhou, J. J., Robertson, G. R. & Lee, V. W. Vitamin D in vascular calcification: A double-edged sword?. *Nutrients* 10, 5 (2018).
31. Ketteler, M. *et al.* Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. *Kidney Int.* 92(1), 26–36 (2017).
32. Drolet, M. C., Arsenault, M. & Couet, J. Experimental aortic valve stenosis in rabbits. *J. Am. Coll. Cardiol.* 41(7), 1211–1217 (2003).
33. Gutierrez, O. *et al.* Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *J. Am. Soc. Nephrol.* 16(7), 2203–2215 (2005).
34. Kim, I. Y. *et al.* Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. *Int. Urol. Nephrol.* 50(12), 2255–2260 (2018).

**Author contributions**
I.Y.K. and S.B.L. designed the study. I.Y.K., B.M.Y., M.J.K., S.R.K., H.J.K., and H.R. analyzed and interpreted data. I.Y.K. and S.B.L. wrote the manuscript. S.H.S., E.Y.S., D.W.L., and S.B.L. supervised the study. All authors reviewed and approved the final manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-04981-x.

**Correspondence** and requests for materials should be addressed to S.B.L.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022